JP2022529943A5 - - Google Patents

Info

Publication number
JP2022529943A5
JP2022529943A5 JP2021561663A JP2021561663A JP2022529943A5 JP 2022529943 A5 JP2022529943 A5 JP 2022529943A5 JP 2021561663 A JP2021561663 A JP 2021561663A JP 2021561663 A JP2021561663 A JP 2021561663A JP 2022529943 A5 JP2022529943 A5 JP 2022529943A5
Authority
JP
Japan
Prior art keywords
interferon
type
composition according
directed
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021561663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529943A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/028296 external-priority patent/WO2020214690A1/en
Publication of JP2022529943A publication Critical patent/JP2022529943A/ja
Publication of JP2022529943A5 publication Critical patent/JP2022529943A5/ja
Priority to JP2025032100A priority Critical patent/JP2025084914A/ja
Pending legal-status Critical Current

Links

JP2021561663A 2019-04-15 2020-04-15 がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 Pending JP2022529943A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025032100A JP2025084914A (ja) 2019-04-15 2025-02-28 がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962920140P 2019-04-15 2019-04-15
US62/920,140 2019-04-15
PCT/US2020/028296 WO2020214690A1 (en) 2019-04-15 2020-04-15 Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025032100A Division JP2025084914A (ja) 2019-04-15 2025-02-28 がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物

Publications (2)

Publication Number Publication Date
JP2022529943A JP2022529943A (ja) 2022-06-27
JP2022529943A5 true JP2022529943A5 (cg-RX-API-DMAC7.html) 2023-04-19

Family

ID=70554222

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561663A Pending JP2022529943A (ja) 2019-04-15 2020-04-15 がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物
JP2025032100A Pending JP2025084914A (ja) 2019-04-15 2025-02-28 がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025032100A Pending JP2025084914A (ja) 2019-04-15 2025-02-28 がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物

Country Status (8)

Country Link
US (3) US11136353B2 (cg-RX-API-DMAC7.html)
EP (1) EP3955957A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022529943A (cg-RX-API-DMAC7.html)
KR (1) KR20210153092A (cg-RX-API-DMAC7.html)
CN (1) CN113993540A (cg-RX-API-DMAC7.html)
AU (1) AU2020258384B2 (cg-RX-API-DMAC7.html)
CA (1) CA3136602A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020214690A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399219B2 (en) * 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
US20240076355A1 (en) * 2021-01-14 2024-03-07 AskGene Pharma, Inc. Interferon Prodrugs and Methods of Making and Using the Same
KR20230157448A (ko) * 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
KR20240021943A (ko) * 2021-06-18 2024-02-19 남미 테라퓨틱스, 인크. 암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법
US20240390506A1 (en) * 2021-09-28 2024-11-28 Suzhou Fuse Biosciences Limited Immunoconjugates containing tnf-alpha and related methods and compositions thereof
CN115057946B (zh) * 2022-06-30 2023-05-16 四川省医学科学院·四川省人民医院 干扰素在制备抗广谱流感病毒和冠状病毒药物中的应用
WO2024181570A1 (ja) 2023-03-02 2024-09-06 大鵬薬品工業株式会社 抗cd138抗体を含む抗体薬物複合体
WO2025201363A1 (zh) * 2024-03-27 2025-10-02 高雄医学大学 细胞因子阻断抗体及其应用
WO2026117686A1 (en) 2024-11-27 2026-06-04 Nammi Therapeutics, Inc. FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2004213565A1 (en) 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항-ctla-4 항체의 용도
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
US20080064862A1 (en) 2004-12-29 2008-03-13 Avigenics, Inc. Transgene expression in a avians
KR20080026135A (ko) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
US8067548B2 (en) 2007-07-26 2011-11-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
US9272029B2 (en) 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
EP2116768B1 (en) 2008-05-09 2016-07-27 Alstom Technology Ltd Burner
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
HRP20150664T1 (hr) 2010-12-03 2015-07-31 Adamed Sp. Z O.O. Antikancerogeni fuzijski protein
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
EP2984171A2 (en) 2013-04-10 2016-02-17 Skau Aps Peptides having immune suppresive domains for transfection
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
US10435695B2 (en) 2016-09-08 2019-10-08 The Government of the United States of America, as represented by the Secretary of Homeland Security Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences
JP2020528878A (ja) 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がん治療用インターフェロンプロドラッグ

Similar Documents

Publication Publication Date Title
JP2025084914A (ja) がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物
HRP20210876T1 (hr) Anti-tmprss2 antitijela i fragmenti koji vezuju antigen
CN110740754A (zh) 一种抗间皮素抗体及其抗体药物缀合物
JP2021521822A5 (cg-RX-API-DMAC7.html)
JP2022512043A5 (cg-RX-API-DMAC7.html)
JP2020531043A5 (cg-RX-API-DMAC7.html)
JP2022520998A5 (cg-RX-API-DMAC7.html)
JP2018520092A5 (cg-RX-API-DMAC7.html)
JP2021512151A5 (cg-RX-API-DMAC7.html)
JP2019506869A5 (cg-RX-API-DMAC7.html)
JP2003523771A5 (cg-RX-API-DMAC7.html)
EP4277707A1 (en) Interferon prodrugs and methods of making and using the same
CN106714831A (zh) 新的抗‑rnf43抗体和使用方法
WO2018119118A4 (en) Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
HRP20110599T1 (hr) Antitijela protiv toksina clostridium difficile i njihove primjene
JP2023123649A5 (cg-RX-API-DMAC7.html)
CA2755686A1 (en) Methods and compositions for bi-specific targeting of cd19/cd22
JP2019524640A5 (cg-RX-API-DMAC7.html)
Bera et al. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability
CN115916839A (zh) 抗pdl1×egfr的双特异性抗体
JP2023544143A5 (cg-RX-API-DMAC7.html)
HRP20161449T1 (hr) Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena
JP2024510811A5 (cg-RX-API-DMAC7.html)
JP2022548364A5 (cg-RX-API-DMAC7.html)